drugset / Trial / NCT00091819

Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus

NCT00091819

Phase 3 Completed 862 enrolled Cumberland Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Study 0017 compares the safety and effectiveness of an investigational drug, telavancin, and an approved drug, vancomycin, for the treatment of complicated skin and skin structure infections.

Timeline

Start
2005-01
Primary completion
2006-06
Completion
2006-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Telavancin Other / unclassified 10 mg/kg Intravenous
Comparator Vancomycin Other / unclassified 1 g Intravenous